Akshaya Keerti M.D.

PGY-1 Internal Medicine

[Akshaya Keerti M.D. @AkshayaKeerti]

My name is Akshaya Keerti, 🇮🇳🇵🇭, a graduate of @MCU1904 and current postdoc research scholar in Infectious Diseases @uofl ( @UofLHealth ). I’m excited to be applying to #Match2026 in #InternalMedicine!

AAMC ID: 16769253

Wishing all applicants the best this season! #MedTwitter

[Samuel Hume @DrSamuelBHume]

One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results

I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore

[Akshaya Keerti M.D. @AkshayaKeerti]

@drakhilkapoor1 @VanitaNoronha @DrVijayPatil11 @KVanLoonMD @trikha_mehak @ACTREC_TMC @SuyogCancer @ullas_batra @JCO_ASCO @CelineHoyek28 @oncodaily Congratulations sir. Looking forward to seeing you at ASCO.

[Akshaya Keerti M.D. @AkshayaKeerti]

@MasterAi254 Guide

[Akshaya Keerti M.D. @AkshayaKeerti]

@AndrewBolis Hustle

[Akshaya Keerti M.D. @AkshayaKeerti]

@NadzuAI Start

[Akshaya Keerti M.D. @AkshayaKeerti]

@AndrewBolis Gpt

[Nishant Rajendra Tiwari @Nischistocyte]

🧬 Classical CD5-based immunophenotypes in B-cell LPDs.
📚 Educational tweet, not medical advice.

✳️ CD5 +ve B-cell LPDs

CLL/SLL:
CD5+, CD23+, CD200+, Cyclin D1-ve, t(11;14)-ve

Mantle Cell Lymphoma:
CD5+, CD23-ve, CD200-ve, Cyclin D1+, t(11;14)+, SOX11+ (Useful if cyclin D1 is negative but typically positive in most cases)

✳️ CD5-ve, CD10+ B-cell LPDs

Follicular lymphoma:
CD5-ve, CD10+, BCL6+, BCL2+, t(14;18)+ [15% cases are BCL2-ve and t(14;18)-ve]

Burkitt lymphoma:
CD5-ve, CD10+, BCL6+, BCL2-ve, MYC rearranged, Ki-67 ≥95%

DLBCL, GCB type:
CD5-ve, CD10+, BCL6+, BCL2+, IRF4/MUM1-ve

DLBCL with IRF4 rearrangement:
CD5-ve, CD10+, BCL6+, IRF4/MUM1+

✳️ CD5-ve CD10-ve B-cell LPDs

Hairy cell leukemia:
CD5-ve, CD10-ve, CD103+, CD25+, CD11c+ (Confirmed with CD123+, Annexin A1+, and BRAF V600E mutated)

Marginal zone lymphoma:
CD5-ve, CD10-ve, CD103-ve, Cytoplasmic Ig+, and MYD88 wild type

Lymphoplasmacytic lymphoma (LPL):
CD5-ve, CD10-ve, CD103-ve, Cytoplasmic Ig+, and MYD88 mutated

DLBCL, GCB:
CD5-ve, CD10-ve, BCL6+, IRF4/MUM1-ve

DLBCL, Non-GCB:
CD5-ve, CD10-ve, BCL6+ve, IRF4/MUM1+ve

DLBCL, Post-GCB:
CD5-ve, CD10-ve, BCL6-ve, IRF4/MUM1+

🔑 Key pointers:
‼️DLBCL can present across CD10 expression groups
‼️Post-GCB terminology is per the gene expression profiling (GEP)/molecular classification
‼️MYD88 L265P is mutated in ~90–95% of LPL cases

Open for feedback/corrections.

[Image AI Generated]

[Akshaya Keerti M.D. @AkshayaKeerti]

@snaqvi1990 Hello Dr Naqvi. I am currently on a J1. Will the position offer j1 sponsorship? I can switch my visa sponsor without having to go back to home country or taking a visa interview. I am already here in US as a research Assistant.

[Akshaya Keerti M.D. @AkshayaKeerti]

@Oliver__Hahn @calico Hello Doc. I’m highly interested in applying for this position. Where do I apply?

[Akshaya Keerti M.D. @AkshayaKeerti]

@imghelpinghand Intrested

[Dr Rishabh Jain @DrRishabhOnco]

🚨 Practice-changing 1L PD-L1+ mTNBC data (CPS ≥10) 🚨
ASCENT-04 / KEYNOTE-D19 just compared:

🧬 Sacituzumab govitecan (SG) + Pembrolizumab
vs
💉 Chemo (taxane or Gem-Carbo) + Pembrolizumab

📌 Primary endpoint: PFS (BICR) ✅
⏳ mPFS: 11.2 vs 7.8 months
📉 HR 0.65 (95% CI 0.51–0.84), P <0.001

🎯 ORR: 60% vs 53%
⏱️ DoR: 16.5 vs 9.2 months (much more durable responses 🔥)

🛑 Discontinuation due to AEs: 12% vs 31% (big practical win)
⚠️ Grade ≥3 AEs: 71% vs 70% (similar overall, different toxicity style)

🧠 OS: immature (not reached yet)

💡 Takeaway: SG + Pembro delivers stronger & longer disease control vs chemo + pembro in previously untreated PD-L1+ advanced TNBC.
This could be a new frontline backbone if guidelines follow. 👑

🔖 Save this for your next TNBC tumor board
📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #BreastCancer #TNBC @OncoAlert @myesmo @esmo_open @asco @stolaney1 @PTarantinoMD

[Akshaya Keerti M.D. @AkshayaKeerti]

@Nischistocyte Thank you so much @Nischistocyte for the kind words

[Akshaya Keerti M.D. @AkshayaKeerti]

We have taller buildings but shorter tempers, more knowledge but less wisdom. Progress means nothing if compassion can’t keep up. 💭
New blog: The Paradox of Progress.
https://t.co/T38nGedceq
#ParadoxOfProgress #Empathy #Mindfulness #EmotionalIntelligence #HumanConnection

[OU College of Medicine @OUCollegeofMed]

@NEJM recently published a Letter to the Editor by @ouhealth and @StephensonCC HemOnc Fellow Nishant R. Tiwari, MD @Nischistocyte (senior author), IM Resident Satya Arepalli, MD, and Professor James N. George, MD, on Fetal Hereditary TTP 👏

https://t.co/sDNgyasXl8

[Akshaya Keerti M.D. @AkshayaKeerti]

@RayPortelaMD @MCU1904 @uofl @UofLHealth Thanks. To you too!

[Akshaya Keerti M.D. @AkshayaKeerti]

My name is Akshaya Keerti, 🇮🇳🇵🇭, a graduate of @MCU1904 and current postdoc research scholar in Infectious Diseases @uofl ( @UofLHealth ). I’m excited to be applying to #Match2026 in #InternalMedicine!

AAMC ID: 16769253

Wishing all applicants the best this season! #MedTwitter

[Akshaya Keerti M.D. @AkshayaKeerti]

@RayPortelaMD @MayoClinic All the best Doc!

[Dr Rishabh Jain @DrRishabhOnco]

Osimertinib: shining in trials ✨, stumbling in the real world 🫁

📌 Retrospective US cohort (n=1323) | JTO 2025

🦾 1L Osimertinib in EGFRm NSCLC

Median OS: real-world shorter (28.6 mo [vs 38.6 mo in FLAURA]) 📉

2-yr survival: 58% [vs 74%]

5-yr survival: 18% [vs 29%]

29% died before 2L ❌
33% never received 2L

📊 Risk factors for poor survival:
•ECOG ≥2 ⚡
•Liver metastases 🩸
•TP53 co-mutation 🧬
•L858R subtype 🧩

⚠️ Key insight: 95% of patients carried ≥1 poor-risk feature ➝ real-world outcomes lag far behind trial promise.

🔑 Takeaway: Osimertinib remains standard, but many patients need better frontline strategies, esp. those trial-ineligible.

📓Sabari JK, Yu HA, Mahadevia PJ, et al. J Thorac Oncol 2025.

DOI: https://t.co/pefx0lm9Es

#OncoTwitter #MedTwitter #LungCancer #TargetedTherapy
@OncoAlert @myesmo @ASCO @IASLC_JTO

[Akshaya Keerti M.D. @AkshayaKeerti]

@SuyogCancer Hello how to join?

[Akshaya Keerti M.D. @AkshayaKeerti]

@Doctors_GUILD C-much